港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

禮邦醫藥-B

30.280

+4.78018.75%

成交量：127.13萬

成交額：3,713.88萬

市值：102.91億

市盈率：- -

高：31.040

開：26.900

低：26.020

收：25.500

52周最高：46.820

52周最低：22.720

股本：3.40億

香港流通股本：2.27億

量比：0.16

換手率：0.56%

股息：- -

股息率：- -

淨資產收益率：--

總資產收益率：-33.01%

市淨率：17.68

市盈率(LYR):- -

市銷率: 291.24

資料載入中...

總覽公司新聞公告

禮邦醫藥(09637.HK)獲GIC及LAV合計增持逾132萬股涉資近5900萬港元

禮邦醫藥(09637)獲GIC及LAV合計增持逾132萬股涉資近5900萬港元

港股異動 | 禮邦醫藥-B(09637)早盤升逾13% 短期錯殺後股價快速修復 AP301商業化即將落地

異動解讀｜禮邦醫藥-B盤中上漲7.92%，報28.8港元

異動解讀｜禮邦醫藥-B盤中下跌21.6%，報23.66港元

55家公司港股通新貴即將喜迎北水流入入通門檻或已抬升至102.67億港元

禮邦醫藥（09637.HK）正式在香港聯合交易所主板掛牌上市

禮邦醫藥(09637)今日登陸港交所：垂直慢病賽道跑出 Biotech 成長新範式

新股首日 |「腎病創新藥第一股」禮邦醫藥首掛上市，早盤升逾90%，一手賺2112港元

異動解讀 | 新股上市首日受熱捧，禮邦醫藥-B盤中暴漲84.16%

【新股IPO】禮邦醫藥－B(09637)首掛開報42.00港元較招股價高85.84%

異動解讀｜禮邦醫藥-B盤中上漲80.53%，上市首日獲資金熱捧

禮邦醫藥-B(09637.HK)香港公開發售獲963.56倍認購 6月29日上市

禮邦醫藥-B首發超購近964倍 6月29日掛牌　募資約12.83億元港元

新股暗盤 | 禮邦醫藥-B(09637)暗盤收漲94% 下周一登陸港交所

老虎暗盤 | 三家新股正在暗盤交易！白鴿在線升逾208%、禮邦醫藥升逾76%、海光芯正升逾53%

老虎资讯综合

一圖讀懂禮邦醫藥(09637)港股IPO

新股消息 | 禮邦醫藥(09637)引入11家頂級基石投資者創近年港股18A市場最強陣容

《新股》騰訊(00700.HK)參投禮邦醫藥(09637.HK)今起招股入場費2,282.79元

阿斯达克财经

新股招股 | 禮邦醫藥-B今起招股，一手入場費2282.79港元

老虎资讯综合

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/09637/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"09637","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09637\",,,,,undefined,":{"symbol":"09637","market":"HK","secType":"STK","nameCN":"禮邦醫藥-B","latestPrice":30.28,"timestamp":1783066093492,"preClose":25.5,"halted":0,"volume":1271300,"delay":0,"changeRate":0.1874509803921569,"floatShares":227000000,"shares":339852231,"eps":0,"marketStatus":"已收盤","change":4.78,"latestTime":"07-03 16:08:13","open":26.9,"high":31.04,"low":26.02,"amount":37138772,"amplitude":0.196863,"askPrice":30.28,"askSize":200,"bidPrice":30,"bidSize":100,"shortable":0,"etf":0,"ttmEps":-2.443,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1783301400000},"marketStatusCode":5,"adr":0,"listingDate":1782662400000,"exchange":"SEHK","adjPreClose":25.5,"openAndCloseTimeList":[[1783042200000,1783051200000],[1783054800000,1783065600000]],"volumeRatio":0.162396,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09637\",,,,,undefined,":{"symbol":"09637","floatShares":227000000,"roa":"-33.01%","roe":"--","lyrEps":0,"volumeRatio":0.162396,"shares":339852231,"dividePrice":0,"high":31.04,"amplitude":0.196863,"preClose":25.5,"low":26.02,"week52Low":22.72,"pbRate":"17.68","psRate":"291.24","week52High":46.82,"institutionHeld":0,"latestPrice":30.28,"committee":-0.333333,"eps":0,"divideRate":0,"volume":1271300,"delay":0,"ttmEps":-2.443,"open":26.9,"prevYearClose":22.6,"prevWeekClose":22.6,"prevMonthClose":45.92,"prevQuarterClose":45.92,"fiveDayClose":22.6,"twentyDayClose":22.6,"sixtyDayClose":22.6},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/09637\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"09637\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"09637\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/09637\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"09637","date":"2026-07-02","current":-12.394597,"percent":0.666667,"low":-18.066068,"twenty":-18.04018,"median":-14.01511,"eighty":-9.55472,"high":-8.87585,"avg":-13.743035,"sd":4.320048,"marketCap":8666231890},"quantilePoints":[{"date":"2026-06-26","current":-8.87585,"twenty":-8.87585,"median":-8.87585,"eighty":-8.87585,"marketCap":7680660420},{"date":"2026-07-02","current":-10.0073,"twenty":-18.04018,"median":-14.01511,"eighty":-9.55472,"marketCap":8666231890}],"updateTime":1783082866786},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"09637\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2648668875","title":"禮邦醫藥(09637.HK)獲GIC及LAV合計增持逾132萬股 涉資近5900萬港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2648668875","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648668875?lang=zh_tw&edition=fundamental","pubTime":"2026-07-03 18:07","pubTimestamp":1783073222,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09637","BK1515","09939","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648668873","title":"禮邦醫藥(09637)獲GIC及LAV合計增持逾132萬股 涉資近5900萬港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2648668873","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648668873?lang=zh_tw&edition=fundamental","pubTime":"2026-07-03 18:07","pubTimestamp":1783073222,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，6月29日，礼邦医药(09637)获两名重要机构股东同步增持。其中，新加坡政府投资公司（GIC Private Limited）以每股44.0844港元增持87.2万股，总金额约3844.16万港元，持股增至1610.03万股，占比7.09%。同日，LAV Asset Management (Hong Kong) Limited以每股45.0615港元增持45万股，涉资约2027.78万港元，持股增至约1634.73万股，占比7.20%。两家机构合计增持逾132万股，累计投入约5872万港元，彰显出对礼邦医药长期价值的认可。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1462987.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","09939","09637","BK1515","BK1161","BK4104","GIC","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648767637","title":"港股異動 | 禮邦醫藥-B(09637)早盤升逾13% 短期錯殺後股價快速修復 AP301商業化即將落地","url":"https://stock-news.laohu8.com/highlight/detail?id=2648767637","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648767637?lang=zh_tw&edition=fundamental","pubTime":"2026-07-03 10:05","pubTimestamp":1783044323,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，礼邦医药-B现涨超13%，截至发稿，涨10.75%，报28.24港元，成交额844.09万港元。据悉，核心产品AP301已进入NDA冲刺阶段，距商业化落地仅12-24个月窗口。值得注意的是，礼邦医药上一交易日股价出现“瀑布杀”，但剔除开盘竞价后，真正把股价砸到26港元下方的连续竞价卖单，合计不足24万股，只占全天827万股成交量的不到3%。向前看，30元为短期阻力位，一旦放量突破并站稳，可以确认修复趋势成立。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1462730.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","09939","VXUS","09637","BK4588","BK1161","159938","BK4585","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145125055","title":"異動解讀｜禮邦醫藥-B盤中上漲7.92%，報28.8港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1145125055","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145125055?lang=zh_tw&edition=fundamental","pubTime":"2026-07-03 09:48","pubTimestamp":1783043322,"startTime":"0","endTime":"0","summary":"7月3日，礼邦医药-B盘中上涨7.92%，报28.8港元/股，成交额472.29万港元。礼邦医药成立于2018年，是一家专注肾脏疾病领域的生物制药企业，拥有覆盖高磷血症、肾性贫血、IgA肾病、糖尿病肾病等多适应症的产品管线。核心产品AP301为治疗高磷血症的口服磷结合剂，已完成中国III期注册临床试验，预计近期提交新药上市申请，目前正在中美推进全球III期关键多中心临床试验。公司于6月29日以22.60港元/股的发行价登陆港交所，上市首日收涨103.54%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104833923","title":"異動解讀｜禮邦醫藥-B盤中下跌21.6%，報23.66港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1104833923","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104833923?lang=zh_tw&edition=fundamental","pubTime":"2026-07-02 09:47","pubTimestamp":1782956834,"startTime":"0","endTime":"0","summary":"7月2日，礼邦医药-B盘中下跌21.6%，报23.66港元/股，成交额2733.63万港元。该股于6月29日以22.60港元/股的发行价登陆港交所，上市首日收涨103.54%报46.00港元，此后股价持续回落，目前已接近发行价水平。礼邦医药成立于2018年，是一家专注肾脏疾病领域的生物制药企业，拥有覆盖高磷血症、肾性贫血、IgA肾病、糖尿病肾病等多适应症的产品管线。核心产品AP301为治疗高磷血症的口服磷结合剂，已完成中国III期注册临床试验，预计近期提交新药上市申请。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647453054","title":"55家公司港股通新貴即將喜迎北水流入 入通門檻或已抬升至102.67億港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2647453054","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647453054?lang=zh_tw&edition=fundamental","pubTime":"2026-07-01 10:09","pubTimestamp":1782871774,"startTime":"0","endTime":"0","summary":"核心规则：市值门槛动态调整截至2026年6月30日，港股通实际纳入门槛已升至102.67亿，剔除门槛达66.89亿。这一指标直接决定了个股在指数中的权重与港股通资格。对于不同上市时长的公司，要求有所不同：对于上市公司而言，维持日均万五左右的换手率是保住港股通资格的关键。数据截止日为每年的6月30日和12月31日，这也是上市公司\"冲关\"港股通的关键时间窗口。","market":"hk","thumbnail":"https://static.tigerbbs.com/0cf777090175126e4590c3b8afdfe41e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/0cf777090175126e4590c3b8afdfe41e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1461288.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["00376","06656","01440","06872","02142","02729","01609","02670","06658","01866","07688","00340","03277","01081","01191","06938","01672","02726","02616","01956","01511","01133","00600","01021","02553","09637","01286","01779","00863","01879","01236","03388","02335","03625","06636","02723","09630","00100","00412","07666","02632","02272","03887","02526","02672","06675","03310","02696","07630","01651","BK4588","00068","01392","03355","BK4585","03661","06106"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2647371593","title":"禮邦醫藥（09637.HK）正式在香港聯合交易所主板掛牌上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2647371593","media":"美通社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647371593?lang=zh_tw&edition=fundamental","pubTime":"2026-06-29 20:00","pubTimestamp":1782734400,"startTime":"0","endTime":"0","summary":"礼邦医药于香港联合交易所主板挂牌上市  本次发售引入阵容强大的基石投资者，包括 GIC、Loomis Sayles、RTW、SymBiosis、腾讯、Cormorant、Dymon Asia、广发基金、汇添富、易方达及正心谷等知名机构。管理层寄语 礼邦医药联合创始人、首席执行官及董事会主席夏国尧博士表示：\"在香港联合交易所主板上市，是礼邦医药发展历程中的重要里程碑。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4993833_ZH93833_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["09939","IPOS","09637","BK1161","BK1515","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647477123","title":"禮邦醫藥(09637)今日登陸港交所：垂直慢病賽道 跑出 Biotech 成長新範式","url":"https://stock-news.laohu8.com/highlight/detail?id=2647477123","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647477123?lang=zh_tw&edition=fundamental","pubTime":"2026-06-29 10:45","pubTimestamp":1782701102,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，6月29日，礼邦医药 - B正式在港交所主板挂牌，成为港股市场首家纯肾病赛道的 18A 创新药企。截至发稿时，礼邦医药股价44.8港元，涨超98%，市值超过150亿港元。这种 “慢赛道里的强卡位”，是 Biotech 最扎实的安全垫：肾病患者用药周期长达数年至十余年，依从性稳定、复购率高，单患者全生命周期价值远高于多数肿瘤适应症；且赛道竞争缓和，无需面对激烈的价格战，更易形成稳定、可预测的现金流模型。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1460168.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","XBI","BK1515","HEXmain","BK4585","BK1161","09939","BK4588","BK4581","09637","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647394342","title":"新股首日 |「腎病創新藥第一股」禮邦醫藥首掛上市，早盤升逾90%，一手賺2112港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2647394342","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647394342?lang=zh_tw&edition=fundamental","pubTime":"2026-06-29 10:21","pubTimestamp":1782699706,"startTime":"0","endTime":"0","summary":"礼邦医药-B今日首挂上市，发行价22.6港元，每手100股，集资净额约11.81亿港元。公司聚焦肾病疗法，核心产品AP301用于治疗高磷血症，已完成中国III期注册临床试验，预计近期提交新药申请，并正在中美推进全球III期关键临床试验。","market":"hk","thumbnail":"https://community-static.tradeup.com/news/477792228558ae5ee6ba159bc242b6a4","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/477792228558ae5ee6ba159bc242b6a4"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1460114.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","IPOS","159938","BK1515","BK1574","159992","09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189776695","title":"異動解讀 | 新股上市首日受熱捧，禮邦醫藥-B盤中暴漲84.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=1189776695","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189776695?lang=zh_tw&edition=fundamental","pubTime":"2026-06-29 09:35","pubTimestamp":1782696934,"startTime":"0","endTime":"0","summary":"礼邦医药-B今日盘中股价大幅上涨84.16%，引发市场高度关注。消息面上，礼邦医药-B作为新股于今日正式登陆港交所主板上市。新股上市首日往往受到市场资金的集中关注，投资者对公司未来发展前景的乐观预期推动了股价的强劲表现。根据相关报道，礼邦医药-B与白鸽在线、海光芯正等其他新股同步于今日在港交所挂牌交易。新股上市通常伴随着较高的市场流动性和投资者兴趣，这可能是推动该股今日盘中出现显著涨幅的重要原因。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647344760","title":"【新股IPO】禮邦醫藥－B(09637)首掛開報42.00港元 較招股價高85.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2647344760","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647344760?lang=zh_tw&edition=fundamental","pubTime":"2026-06-29 09:34","pubTimestamp":1782696861,"startTime":"0","endTime":"0","summary":"金吾财讯 | 礼邦医药－B(09637)首挂开报42.00港元，较招股价高85.84%，盘前成交额2.69亿港元。不计手续费，每手100股，账面赚1940港元。据招股结果显示，股份最终发售价厘定为每股22.60港元，香港公开发售获大幅超额认购，有效申请145,729份，认购倍数约963.56倍，一手中签率为6.00%。国际发售获适度超额认购，认购倍数约19.77倍。","market":"nz","thumbnail":"https://static.szfiu.com/news/20220324/YjY3NDkzOTMxMjg3NTcxMDI1Mg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20220324/YjY3NDkzOTMxMjg3NTcxMDI1Mg==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984672","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","159938","09637","09939","EWH","BK1515","BK1574","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149112653","title":"異動解讀｜禮邦醫藥-B盤中上漲80.53%，上市首日獲資金熱捧","url":"https://stock-news.laohu8.com/highlight/detail?id=1149112653","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149112653?lang=zh_tw&edition=fundamental","pubTime":"2026-06-29 09:33","pubTimestamp":1782696835,"startTime":"0","endTime":"0","summary":"6月29日，礼邦医药-B正式登陆港交所，盘中上涨80.53%，报41.26港元，成交额2.82亿港元。消息面上，礼邦医药-B以每股22.60港元定价发行，公开发售阶段获963.56倍超额认购，国际配售获19.77倍认购，市场追捧力度强劲。此前暗盘收涨约88%至94%，已充分反映市场对该标的的乐观预期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646636649","title":"禮邦醫藥-B(09637.HK)香港公開發售獲963.56倍認購 6月29日上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2646636649","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646636649?lang=zh_tw&edition=fundamental","pubTime":"2026-06-26 23:07","pubTimestamp":1782486421,"startTime":"0","endTime":"0","summary":"格隆汇6月26日丨礼邦医药-B(09637.HK)公告，公司全球发售56,755,400股H股，每股H股22.60港元，所得款项净额11.81亿港元。香港公开发售股份数目占全球发售股份数目10%，获认购963.56倍；国际发售股份数目占全球发售股份90%，获认购倍19.77倍。\r\n\r\n　　假设全球发售于2026年6月29日(星期一)上午八时正或之前(香港时间)成为无条件，预期H股将于2026年6月29日(星期一)上午九时正(香港时间)开始在联交所买卖。H股将以100股H股为一手买卖单位进行交易，H股的股份代号为09637。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260626/32291951.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["09939","159938","BK1161","BK1574","BK1515","09637","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198163419","title":"禮邦醫藥-B首發超購近964倍  6月29日掛牌　募資約12.83億元港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1198163419","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198163419?lang=zh_tw&edition=fundamental","pubTime":"2026-06-26 22:45","pubTimestamp":1782485148,"startTime":"0","endTime":"0","summary":"6月26日晚间，礼邦医药（江苏）股份有限公司公布全球发售最终定价及配发结果。公司以每股22.60港元发售H股，共计发行5,675.54万股。按发售价计算，公司预计募资总额约12.83亿元港元，扣除相关开支后的净筹资额约11.81亿元港元。礼邦医药-B将于6月29日（周一）在香港联交所主板挂牌交易，每手100股。最终公开发售部分维持原定占比10%，合计配售567.56万股H股，未触发回补机制。各基石投资者均承诺自上市日起六个月禁售，至2026年12月28日方可解除。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646357850","title":"新股暗盤 | 禮邦醫藥-B(09637)暗盤收漲94% 下周一登陸港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=2646357850","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646357850?lang=zh_tw&edition=fundamental","pubTime":"2026-06-26 20:14","pubTimestamp":1782476058,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，今日辉立暗盘交易显示，港股“肾病创新药第一股”礼邦医药-B(09637)暗盘收报43.88港元，较发售价22.60港元上涨94.16%。每手100股，不计手续费，每手账面赚2128港元。据悉，礼邦医药的IPO引发了全市场的瞩目，公司不仅手握“1 款商业化产品 + 7 款临床阶段候选药物” 的完整管线矩阵，更集齐了横跨全球主权基金、百年资管、专业生命科学基金与产业资本的11家基石投资者，创下近年18A 市场基石阵容的天花板。礼邦医药将于6月29日(星期一)在港交所挂牌。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1459666.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","09637","BK1515","09939","BK1161","HEXmain","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105013507","title":"老虎暗盤 | 三家新股正在暗盤交易！白鴿在線升逾208%、禮邦醫藥升逾76%、海光芯正升逾53%","url":"https://stock-news.laohu8.com/highlight/detail?id=1105013507","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105013507?lang=zh_tw&edition=fundamental","pubTime":"2026-06-26 16:10","pubTimestamp":1782461402,"startTime":"0","endTime":"0","summary":"6月26日，三家新股正在暗盘交易，情况如下：$礼邦医药-B(09637)$暗盘升76.11%，股价报39.8港元，每手股数100股，一手账面赚1720港元，总市值超135亿港元。 $海光芯正(01191)$暗盘升53.6%，股价报175.1港元，每手股数50股，一手账面赚3075港元，总市值超156亿港元。 $白鸽在线(02672)$暗盘升208.08%，股价报48.06港元，每手股数200股，一手账面赚6492港元，总市值超154.09亿港元。","market":"hk","thumbnail":"https://static.tigerbbs.com/6b69e234a63c2c0a69ccede7b0faaa18","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/6b69e234a63c2c0a69ccede7b0faaa18"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"3430ee0e05254278b5a3da84a7b77b4c","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01191","09637","02672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644058114","title":"一圖讀懂禮邦醫藥(09637)港股IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2644058114","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644058114?lang=zh_tw&edition=fundamental","pubTime":"2026-06-19 12:17","pubTimestamp":1781842621,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，港股“肾病创新药第一股”礼邦医药(09637)于2026年6月18日-6月24日招股，预期6月29日上午9时正式在联交所挂牌交易。这家深耕肾脏病领域的创新药企，不仅手握“1 款商业化产品 + 7 款临床阶段候选药物” 的完整管线矩阵，更在港股生物医药板块整体低迷的背景下，集齐了横跨全球主权基金、百年资管、专业生命科学基金与产业资本的11家基石投资者，创下近年18A 市场基石阵容的天花板。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260619/32284519.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1574","BK4588","BK1161","IPOS","09939","09637","BK4585","BK1515","159938","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644757087","title":"新股消息 | 禮邦醫藥(09637)引入11家頂級基石投資者 創近年港股18A市場最強陣容","url":"https://stock-news.laohu8.com/highlight/detail?id=2644757087","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644757087?lang=zh_tw&edition=fundamental","pubTime":"2026-06-18 10:11","pubTimestamp":1781748693,"startTime":"0","endTime":"0","summary":"在这样的行业拐点，礼邦医药的IPO引发了全市场的瞩目。这家深耕肾脏病领域的创新药企，不仅手握“1 款商业化产品 + 7 款临床阶段候选药物” 的完整管线矩阵，更在港股生物医药板块整体低迷的背景下，集齐了横跨全球主权基金、百年资管、专业生命科学基金与产业资本的11家基石投资者，创下近年18A 市场基石阵容的天花板。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1455947.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","09939","09637","VXUS","BK1161","BK4588","BK1574","159938","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644732077","title":"《新股》騰訊(00700.HK)參投禮邦醫藥(09637.HK)今起招股 入場費2,282.79元","url":"https://stock-news.laohu8.com/highlight/detail?id=2644732077","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644732077?lang=zh_tw&edition=fundamental","pubTime":"2026-06-18 09:06","pubTimestamp":1781744760,"startTime":"0","endTime":"0","summary":"生物制药公司礼邦医药公布招股详情，计划全球发售5,675.54万股H股，香港公开发售占约10%，国际配售占约90%，发售价为每股22.6元。每手买卖单位100股，入场费约2,282.79元。认购金额合共8,150万美元，按发售价计算认购约2,825.49万股，占全球发售股份约49.78%。其中腾讯及GIC为礼邦医药上市前投资者，预料在其上市后将持股约10.28%及约5.97%。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20260618090434445_s.png","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20260618090434445_s.png"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1529560/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1529560/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174519175","title":"新股招股 | 禮邦醫藥-B今起招股，一手入場費2282.79港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1174519175","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174519175?lang=zh_tw&edition=fundamental","pubTime":"2026-06-18 08:11","pubTimestamp":1781741501,"startTime":"0","endTime":"0","summary":"6月18日，礼邦医药-B发布公告，公司拟全球发售5675.54万股H股，中国香港发售567.56万股H股，国际发售5107.98股H股；2026年6月18日至6月24日招股；发售价将为每股发售股份22.60港元，H股的每手买卖单位将为100股，Jefferies、BofA Securities及HTSC为联席保荐人；预期H股将于2026年6月29日开始于联交所买卖。按发售价每股H股22.6港元计算，并假设超额配股权未获行使，公司全球发售所得款项净额总额将约为11.808亿港元。","market":"hk","thumbnail":"https://static.tigerbbs.com/03b737852f586e2640047e4e68a010a4","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/03b737852f586e2640047e4e68a010a4"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"新股招股 | 礼邦医药-B今起招股，一手入场费2282.79港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":23,"code":"91000000","status":"200"}]}}